Business
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing.
About this update from Abbott Laboratories
[{"type":"list","items":[{"val":[{"type":"text","content":"Announcement follows receipt of all regulatory clearances necessary for closing","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":220,"olType":false},{"type":"text","content":"ABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing.","length":255,"tagName":"p"},{"type":"text","content":"The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages.","length":341,"tagName":"p"},{"type":"text","content":""Proactively shaping the portfolio to anticipate future medical needs while building long-term shareholder value remains at the core of our strategic framework," said Robert B. Ford, chairman and chief executive officer, Abbott. "The addition of Exact Sciences enhances Abbott's growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health."","length":561,"tagName":"p"},{"type":"text","content":"Strategic fitExact Sciences is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence.","length":189,"tagName":"p"},{"type":"text","content":"This acquisition strengthens Abbott's leadership position and capabilities in diagnostics, positioning the company to advance technologies that are more preventative, predictive and personalized. It expands Abbott's presence in one of the fastest-growing areas of healthcare as cancer incidence continues to rise worldwide. It also adds a new growth ver...